Acrivon Therapeutics (ACRV) Interest & Investment Income (2023 - 2026)

Acrivon Therapeutics (ACRV) has reported Interest & Investment Income for 4 consecutive years, with $860000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 50.29% year-over-year to $860000.0 in Q2 2026; TTM through Jun 2026 was $4.6 million, a 47.63% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 29.58% from the prior year.
• Interest & Investment Income was $860000.0 for Q2 2026 at Acrivon Therapeutics, down from $989000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $2.7 million in Q3 2024 and troughed at $860000.0 in Q2 2026.
• A 4-year average of $1.8 million and a median of $1.7 million in 2023 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income surged 52.6% in 2024 and sank 50.45% in 2026, its largest moves.
• Over 4 years, Interest & Investment Income stood at $1.7 million in 2023, then surged by 39.66% to $2.4 million in 2024, then tumbled by 47.23% to $1.2 million in 2025, then sank by 31.03% to $860000.0 in 2026.
• The last three Interest & Investment Income figures came in at $860000.0 (Q2 2026), $989000.0 (Q1 2026), and $1.2 million (Q4 2025), per Business Quant data.